Proportion of persons with a PsA diagnosis with at least one prescription for the respective DMARDs in 2021 in %
| Women | Men | Total | Total without RA codes | |
| csDMARDs (all) | 63 | 60 | 62 | 60 |
| Methotrexate | 55 | 55 | 55 | 54 |
| Sulfasalazine | 0.3 | 0.2 | 0.3 | 0.2 |
| Leflunomide | 11 | 7.0 | 9.3 | 7.7 |
| Ciclosporin | 0.5 | 0.3 | 0.4 | 0.4 |
| bDMARDs (all) | 48 | 51 | 49 | 50 |
| cs+bDMARD combination | 16 | 15 | 15 | 14 |
| bDMARD monotherapy | 32 | 37 | 33 | 36 |
| TNF-inhibitors | 29 | 32 | 30 | 29 |
| Etanercept | 8.9 | 9.0 | 8.9 | 8.1 |
| Infliximab | 0.8 | 1.1 | 0.9 | 0.7 |
| Adalimumab | 15 | 18 | 16 | 17 |
| Golimumab | 1.9 | 2.7 | 2.2 | 2.0 |
| Certolizumab pegol | 3.4 | 2.1 | 2.9 | 2.7 |
| Ig fusion protein Abatacept | 0.7 | 0.3 | 0.6 | 0.3 |
| IL12/23i Ustekinumab | 3.8 | 4.2 | 3.9 | 4.5 |
| IL17i Secukinumab | 11 | 9.9 | 10 | 11 |
| Ixekizumab | 5.2 | 5.4 | 5.2 | 5.8 |
| IL23i Guselkumab | 3.2 | 3.4 | 3.3 | 3.9 |
| tsDMARDs | ||||
| JAKi Tofacitinib | 2.3 | 1.4 | 1.9 | 1.7 |
| Upadacitinib | 4.1 | 2.4 | 3.5 | 2.9 |
| PDE4i Apremilast | 4.5 | 3.4 | 4.1 | 4.6 |
bDMARDs, biological disease-modifying antirheumatic drugs ; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; DMARDs, disease-modifying antirheumatic drugs; PsA, psoriatic arthritis; RA, rheumatoid arthritis; tsDMARDs, targeted synthetic disease-modifying antirheumatic drugs.